Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Navan (NAVN) Sued Over IPO Disclosures; Investors Face April 24 Deadline - Hagens Berman (PR Newswire) +++ NAVAN Aktie -4,27%

TVARDI Aktie

 >TVARDI Aktienkurs 
2.56 EUR    (TradegateBSX)
Ask: 2.59 EUR / 640 Stück
Bid: 2.53 EUR / 660 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
TVARDI Aktie über LYNX handeln
>TVARDI Performance
1 Woche: -10,6%
1 Monat: -24,3%
3 Monate: -29,9%
6 Monate: -91,7%
1 Jahr: 0%
laufendes Jahr: -29,9%
>TVARDI Aktie
Name:  TVARDI THERAPEUTICS O.N.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1407553072 / A414VY
Symbol/ Ticker:  69C (Frankfurt) / TVRD (NASDAQ)
Kürzel:  FRA:69C, ETR:69C, 69C:GR, NASDAQ:TVRD
Index:  -
Webseite:  https://tvarditherapeutic..
Profil:  Cara Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing new chemical entities designed to alleviate pain and pruritus, also known as itch. The company's primary focus is on treatments targeting the kappa opio..
>Volltext..
Marktkapitalisierung:  25.96 Mio. EUR
Unternehmenswert:  -4.65 Mio. EUR
Umsatz:  3.48 Mio. EUR
EBITDA:  -19.99 Mio. EUR
Nettogewinn:  -12.06 Mio. EUR
Gewinn je Aktie:  -7.21 EUR
Schulden:  0.2 Mio. EUR
Liquide Mittel:  18.52 Mio. EUR
Operativer Cashflow:  -18.9 Mio. EUR
Bargeldquote:  3.3
Umsatzwachstum:  -56.04%
Gewinnwachstum:  86.15%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  TVARDI
Letzte Datenerhebung:  01.04.26
>TVARDI Kennzahlen
Aktien/ Unternehmen:
Aktien: 9.38 Mio. St.
Frei handelbar: 69.78%
Rückkaufquote: -1.77%
Mitarbeiter: 10
Umsatz/Mitarb.: 0.62 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 256.68%
Bewertung:
KGV: -
KGV lG: -
KUV: 13.41
KBV: 0.9
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -346.55%
Operative Marge: -576.39%
Managementeffizenz:
Gesamtkaprendite: -30.87%
Eigenkaprendite: -97.61%
>TVARDI Peer Group
Gesundheit, Dialyse- Behandlung/ Blutwäsche, Nierenerkrankungen & -behandlung
 
31.03.26 - 22:09
 Tvardi Therapeutics GAAP EPS of -$0.78 misses by $0.19 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.03.26 - 22:03
 Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update (GlobeNewswire EN)
 
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026...
08.01.26 - 22:09
 Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation...
28.12.25 - 02:06
 Faruqi & Faruqi LLP: INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (Newsfile)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their OptionsIf you suffere......
23.12.25 - 16:21
 INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
17.12.25 - 16:33
 TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
16.12.25 - 16:42
 Faruqi & Faruqi LLP: TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (Newsfile)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their OptionsIf you suffere......
11.12.25 - 16:18
 TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
04.12.25 - 16:31
 INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
30.11.25 - 15:48
 TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
21.11.25 - 16:12
 TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
18.11.25 - 17:30
 Tvardi (TVRD) May Find a Bottom Soon, Here′s Why You Should Buy the Stock Now (Zacks)
 
Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term....
14.11.25 - 16:33
 SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered losses in Tvardiand would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson......
13.11.25 - 22:42
 Tvardi Therapeutics GAAP EPS of -$0.59 beats by $0.22 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.11.25 - 22:06
 Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update (Business Wire)
 
On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 Results from healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, expected in H1 2026 Cash runway sufficient to fund operations into Q4 2026HOUSTON--(BUSINESS WIRE)--#IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced its financial and operating results for the third quarter ended September 30, 2025, and provided a business update. Third Quarter 2025 and Recent Highlights: Continued to progress its Phase 2 study of TTI-101 in HCC, with topline data anticipated in the first half of 2026. Announced that the IND for its next-generation STAT3 inhibitor, TTI-109, is in effect and that a healthy volunteer study has been initiated, results of which are anticipated in the first half ...
03.11.25 - 16:21
 INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
28.10.25 - 14:33
 TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
23.10.25 - 19:06
 Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRD (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
15.10.25 - 16:03
 TVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights,......
14.10.25 - 19:00
 TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals (Zacks)
 
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Don′t marry, be happy. - Hera Lind
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!